TNF-alpha Neutralization Rate Infliximab ELISA

$1,095.00

The TNA-alpha Neutralization Rate Infliximab ELISA is an agent for the simultaneous quantitative determination of free TNFα, the TNFα neutralization rate (Infliximab activity) and the available therapeutic antibody Infliximab in human serum samples. It consists of a manual, non-automated kit for the determination of 7 samples. The recoveryELISA RTI is for research use only and not to be used in diagnostic procedures.

TNF-alpha Neutralization Rate Infliximab ELISA

The TNF-alpha Neutralization Rate Infliximab ELISA is For Research Use Only

Size: 1×96 wells
Sensitivity: Adalimumab: 0.7 µg/mL; TNFα: 4ng/ml
Dynamic Range: Infliximab: 0.1 – 15 µg/mL; TNFα in sample without Infliximab: 2-400ng/ml; TNFα in sample with Infliximab: 1-160ng/ml
Incubation Time: Overnight
Sample Type: Serum
Sample Size: 60 µL

Controls Included


Assay Background

Tumour necrosis factor (TNFα) is a signalling substance of the immune system which can cause, among other things, the formation of inflammatory mediators in cells. In inflammatory diseases such as rheumatoid arthritis, there is overproduction of TNFα, which can be inhibited by using therapeutic antibodies. Infliximab is an chimeric monoclonal antibody which is used as a TNFα inhibitor. Infliximab binds specifically to the TNFα protein and neutralises the biological effect of TNFα. Infliximab is approved for the treatment of the following diseases: rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis. In therapy using Infliximab, contraindications such as hypersensitivity to Infliximab and also serious infections, sepsis, tuberculosis and cases of opportunistic infections have been noted. Weakening of the body’s defence is produced by the immunosuppressive effect of Infliximab. Excessive neutralization of TNFα during treatment with Infliximab increases the risk of developing opportunistic infections. In view of this, monitoring the treatment antibody levels and degree of neutralization of TNFα would appear useful during therapy using the TNFα inhibitor Infliximab. In comparison with the tests available on the market, the recoveryELISA TNFα Neutralization Rate/Infliximab (RTI) Kit can be used to simultaneously determine the free TNFα target antigen, the available therapeutic antibody Infliximab and its ability to neutralise TNFα.


Related Products

TNF-alpha Neutralization Rate Adalimumab ELISA Assay
Anti-Infliximab (Remicade) ELISA Assay Kit
Infliximab (Remicade) ELISA Assay Kit

Additional Information

Assay Principle


RecoveryELISA is performed in a 96-well microplate. The wells of the microplate are pre-coated with a  specific capture antibody against human TNFα that binds free TNFα from the patient sample. There  occurs a simultaneous incubation of the TNFα levels (with and without the addition of Infliximab) of the  samples and of the detection conjugate (peroxidase conjugate of an anti-TNFα antibody). Incubation  takes place over 16 to 22 hours at 2 to 8°C. After washing, the colour substrate TMB  (tetramethylbenzidine) is added to the wells. After incubation the enzymatic colour reaction is stopped  using a sulphuric acid solution. A colour change from blue to yellow occurs that is optically detected.  Using a wavelength of 450 nm (reference value 620 nm), the optical density (OD) of the reaction  product is measured with a suitable microplate reader.  With the aid of the two calibrations to be performed, an evaluation procedure can be carried out to  determine the concentrations of free TNFα and Infliximab in the patient samples using the measured  OD values. Determination of the therapeutic antibody is based on the principle that the presence of  Infliximab in patient samples leads to a systematic reduction in the recovery of TNFα. The evaluation  is performed using non-linear regression (Marquardt-Levenberg algorithm), the Michaelis-Menten  model from enzyme kinetics and the Langmuir isotherm from surface binding.

Standard Curve


TNF-alpha Neutralization Rate Infliximab ELISA

Documents

Product Documents


Product Citations